Dendritic Cell‐Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes
Advanced Science · 2024
DOI: 10.1002/advs.202402199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Lei Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. Hauptthemen laut MEDLINE: Dendritic Cells, Cancer Vaccines, Lymph Nodes. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Henan Science Fund for Outstanding Young Scholars, Science and technology innovation talents support project of Henan Province.
Abstract (Originalsprache)
Therapeutic cancer vaccines are among the first FDA‐approved cancer immunotherapies. Among them, it remains a major challenge to achieve robust lymph‐node (LN) accumulation. However, delivering cargo into LN is difficult owing to the unique structure of the lymphatics, and clinical responses have been largely disappointing. Herein, inspired by the Migrated‐DCs homing from the periphery to the LNs, an injectable hydrogel‐based polypeptide vaccine system is described for enhancing immunostimulatory efficacy, which could form a local niche of vaccine “hitchhiking” on DCs. The OVA peptide modified by lipophilic DSPE domains in the hydrogel is spontaneously inserted into the cell membrane to achieve “antigen anchoring” on DCs in vivo. Overall, OVA peptide achieves active access LNs through recruiting and “hitchhiking” subcutaneous Migrated‐DCs. Remarkably, it is demonstrated that the composite hydrogel enhances LNs targeting efficacy by approximately six‐fold compared to free OVA peptide. Then, OVA peptide can be removed from the cell surface under a typical acidic microenvironment within the LNs, further share them with LN‐resident APCs via the “One‐to‐Many” strategy (One Migrated‐DC corresponding to Many LN‐resident APCs), thereby activating powerful immune stimulation. Moreover, the hydrogel vaccine exhibits significant tumor growth inhibition in melanoma and inhibits pulmonary metastatic nodule formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou, 450001, China.
- Department of Breast Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 450003, China.
ORCID-Profile: Junjie Liu
Förderung
- National Natural Science Foundation of China
- Henan Science Fund for Outstanding Young Scholars
- Science and technology innovation talents support project of Henan Province
Zitieren
APA
Zhou, L., Zhao, L., Wang, M., Qi, X., Zhang, X., Song, Q., Xue, D., Mao, M., Zhang, Z., Shi, J., Si, P., & Liu, J. (2024). Dendritic Cell‐Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes. Advanced Science. https://doi.org/10.1002/advs.202402199
Vancouver
Zhou L, Zhao L, Wang M, Qi X, Zhang X, Song Q, et al. Dendritic Cell‐Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes. Advanced Science. 2024. doi:10.1002/advs.202402199
BibTeX
@article{Zhou2024,
author = {Zhou, Lei and Zhao, Ling and Wang, Mengyao and Qi, Xu and Zhang, Xin and Song, Qingying and Xue, Dayu and Mao, Meihua and Zhang, Zhenzhong and Shi, Jinjin and Si, Pilei and Liu, Junjie},
title = {Dendritic Cell‐Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202402199}
}
EUVIMED